Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma

Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma

PurposeWe aimed to investigate the restoration of CD8+PD-1+ T cells through adoptive T-cell therapy (ACT) in relation to the prognosis and the therapeutic response to anti-PD-1 in patients with advanced pancreatic cancer (APC).MethodsA total of 177 adult patients who underwent tumor resection as ini...

Full description

Bibliographic Details
Main Authors:	Qian Zhu, Guoliang Qiao, Lefu Huang, Chang Xu, Deliang Guo, Shuo Wang, Jing Zhao, Yuguang Song, Bing Liu, Zheng Chen, Zhiyong Yang, Yufeng Yuan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Oncology
Subjects:	CD8+PD-1+ T cell TCR PDAC tumor resection adoptive cell immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.837560/full

Similar Items

PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
by: Sylvain Simon, et al.
Published: (2018-01-01)

Data on the identification of VRK2 as a mediator of PD-1 function
by: Michael Peled, et al.
Published: (2021-08-01)

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
by: Ching-Yao Yang, et al.
Published: (2020-06-01)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
by: Yiru Long, et al.
Published: (2022-05-01)

Staging Computed Tomography Parameters Predict the Need for Vein Resection during Pancreaticoduodenectomy in Resectable Pancreatic Ductal Adenocarcinoma
by: Rupaly Pande, et al.
Published: (2024-01-01)

Effect of Rapamycin on Exosomes and PD-1/PD-L1 in Human Erythroleukemia HEL Cells
by: QI Lin, et al.
Published: (2022-10-01)

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
by: Rita Balsano, et al.
Published: (2023-03-01)

T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity
by: Nadja Sailer, et al.
Published: (2022-04-01)

PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells
by: Cecilia Pesini, et al.
Published: (2022-12-01)

A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma
by: Benedetta Ferrara, et al.
Published: (2022-09-01)

Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes
by: L Marotte, et al.
Published: (2021-01-01)

Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma
by: Iman M. Ahmad, et al.
Published: (2021-05-01)

Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications
by: Shantel Angstadt, et al.
Published: (2022-01-01)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
by: Tianjiao Li, et al.
Published: (2019-09-01)

Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice
by: Weiqing Jing, et al.
Published: (2017-06-01)

Role of regulation of PD-1 and PD-L1 expression in sepsis
by: Teng Zhang, et al.
Published: (2023-03-01)

Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering
by: Masahiro Okada, et al.
Published: (2023-06-01)

PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay
by: Xiaolong Liang, et al.
Published: (2018-01-01)

Galectins Are Central Mediators of Immune Escape in Pancreatic Ductal Adenocarcinoma
by: Zhengting Jiang, et al.
Published: (2022-11-01)

Metabolism remodeling in pancreatic ductal adenocarcinoma
by: Jin-Tao Li, et al.
Published: (2019-11-01)

Inhibition of ERO1a and IDO1 improves dendritic cell infiltration into pancreatic ductal adenocarcinoma
by: Apple Hui Min Tay, et al.
Published: (2023-12-01)

Divergent Roles of Mitochondria Dynamics in Pancreatic Ductal Adenocarcinoma
by: Cristian Andres Carmona-Carmona, et al.
Published: (2022-04-01)

Oral mycobiota and pancreatic ductal adenocarcinoma
by: Ailin Wei, et al.
Published: (2022-12-01)

Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma
by: Bryn Golesworthy, et al.
Published: (2022-04-01)

KIF2C Facilitates Tumor Growth and Metastasis in Pancreatic Ductal Adenocarcinoma
by: Xing Huang, et al.
Published: (2023-02-01)

The PD1: PD-L1/2 pathway from discovery to clinical implementation
by: Kankana Bardhan, et al.
Published: (2016-12-01)

PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
by: Enrico Munari, et al.
Published: (2021-05-01)

Loss of Cadherin-11 in pancreatic ductal adenocarcinoma alters tumor-immune microenvironment
by: Aimy Sebastian, et al.
Published: (2023-10-01)

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
by: Oliver Kepp, et al.
Published: (2019-10-01)

RNA-Seq-Based TCR Profiling Reveals Persistently Increased Intratumoral Clonality in Responders to Anti-PD-1 Therapy
by: Ekaterina A. Zhigalova, et al.
Published: (2020-04-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Stefania Oliva, et al.
Published: (2018-11-01)

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
by: Pierre Dillard, et al.
Published: (2021-01-01)

Gene Coexpression Network Characterizing Microenvironmental Heterogeneity and Intercellular Communication in Pancreatic Ductal Adenocarcinoma: Implications of Prognostic Significance and Therapeutic Target
by: Chengsi Wu, et al.
Published: (2022-06-01)

Association between <i>AHR</i> Expression and Immune Dysregulation in Pancreatic Ductal Adenocarcinoma: Insights from Comprehensive Immune Profiling of Peripheral Blood Mononuclear Cells
by: Arenida Bartkeviciene, et al.
Published: (2023-09-01)

From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
by: Christopher Montemagno, et al.
Published: (2020-06-01)

PD‐L1 and PD‐L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules
by: Yue Zhang, et al.
Published: (2022-05-01)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01)

The changes in peripheral blood Th17 and Treg ratios in Hashimoto’s thyroiditis are accompanied by differential PD-1/PD-L1 expression
by: Jun Fang, et al.
Published: (2022-08-01)

Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case—Cohort Study
by: Kinan El Husseini, et al.
Published: (2021-09-01)